Stryker Corporation (SYK)
| Market Cap | 116.96B -20.8% |
| Revenue (ttm) | 25.27B +8.8% |
| Net Income | 3.34B +16.7% |
| EPS | 8.64 +16.8% |
| Shares Out | 383.36M |
| PE Ratio | 35.31 |
| Forward PE | 19.50 |
| Dividend | $3.52 (1.15%) |
| Ex-Dividend Date | Jun 30, 2026 |
| Volume | 6,065,780 |
| Open | 307.50 |
| Previous Close | 307.63 |
| Day's Range | 304.00 - 309.08 |
| 52-Week Range | 281.00 - 404.87 |
| Beta | 0.81 |
| Analysts | Buy |
| Price Target | 389.35 (+27.62%) |
| Earnings Date | Apr 30, 2026 |
About SYK
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally inv... [Read more]
Financial Performance
In 2025, Stryker's revenue was $25.12 billion, an increase of 11.16% compared to the previous year's $22.60 billion. Earnings were $3.25 billion, an increase of 8.45%.
Financial StatementsAnalyst Summary
According to 29 analysts, the average rating for SYK stock is "Buy." The 12-month stock price target is $389.35, which is an increase of 27.62% from the latest price.
News
Stryker announces European launch of Pangea Plating System
Stryker (SYK) announced the European launch of its Pangea Plating System, a plating platform for the treatment of a wide range of fracture patterns. Prof. Alex Trompeter, design surgeon and…
Stryker Launches Pangea Plating System and Completes First Case in Europe
AMSTERDAM--(BUSINESS WIRE)--Stryker announced the European launch of its Pangea Plating System, a plating platform for the treatment of a wide range of fracture patterns.
BioStar Capital-Backed Amplitude Vascular Systems' $835M Acquisition by Stryker Reflects Strength of Michigan's Medtech Ecosystem
CHARLEVOIX, Mich.--(BUSINESS WIRE)--BioStar Capital, a venture capital firm focused on transformative medical technologies, has announced a landmark pre-FDA exit of Amplitude Vascular Systems, Inc. (A...
AVS, Now Part of Stryker, Enrolls First Patient in First-in-Human Coronary Intravascular Lithotripsy Study
BOSTON--(BUSINESS WIRE)--Amplitude Vascular Systems (AVS), a medical device company recently acquired by Stryker and focused on treating severely calcified arterial disease, today announced the enroll...
Stryker Transcript: Bank of America Global Healthcare Conference 2026
Leadership reaffirmed commitment to innovation and M&A, with strong recovery plans after a cyber incident. Full-year guidance is maintained, supported by robust demand, operational resilience, and a healthy capital backlog. Mako robotics and new product launches drive growth.
Stryker completes acquisition of Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio
Portage, Michigan, May 07, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK announced that it has completed the acquisition of Amplitude Vascular Systems, Inc. (AVS), a privately held medical technology com...
Stryker declares an $0.88 per share quarterly dividend
Portage, Michigan, May 07, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable July 31, 2026, to shareholders...
Stryker Transcript: AGM 2026
The meeting confirmed strong double-digit sales growth, major acquisitions, and a continued focus on innovation. All board nominees, auditor ratification, and executive compensation were approved. The five-year outlook projects sustained high growth through innovation and acquisitions.
Stryker price target lowered to $330 from $380 at Truist
Truist analyst Richard Newitter lowered the firm’s price target on Stryker (SYK) to $330 from $380 and keeps a Hold rating on the shares. The firm is adjusting its model…
Stryker price target lowered to $394 from $469 at Barclays
Barclays analyst Matt Miksic lowered the firm’s price target on Stryker (SYK) to $394 from $469 and keeps an Overweight rating on the shares. The company’s Q1 results were mixed…
Stryker price target raised to $361 from $357 at Goldman Sachs
Goldman Sachs analyst David Roman raised the firm’s price target on Stryker (SYK) to $361 from $357 and keeps a Neutral rating on the shares after its Q1 earnings. The…
Stryker price target lowered to $385 from $437 at Baird
Baird lowered the firm’s price target on Stryker (SYK) to $385 from $437 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results where…
Stryker price target lowered to $410 from $465 at Bernstein
Bernstein lowered the firm’s price target on Stryker (SYK) to $410 from $465 and keeps an Outperform rating on the shares. The firm notes that given Q1 disruption that was…
Stryker price target lowered to $355 from $365 at Evercore ISI
Evercore ISI lowered the firm’s price target on Stryker (SYK) to $355 from $365 and keeps an Outperform rating on the shares.
Stryker price target lowered to $400 from $445 at JPMorgan
JPMorgan analyst Robbie Marcus lowered the firm’s price target on Stryker (SYK) to $400 from $445 and keeps an Overweight rating on the shares.
Stryker price target lowered to $379 from $397 at BTIG
BTIG lowered the firm’s price target on Stryker (SYK) to $379 from $397 and keeps a Buy rating on the shares. The company’s Q1 revenue came in below consensus as…
Stryker to participate in the Bank of America Securities 2026 Global Healthcare Conference
Portage, Michigan, May 01, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the Bank of America Securities 2026 Global Healthcare Conference on Wednesday, May 13, 2026, at the Encore at...
Stryker price target lowered to $315 from $402 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Stryker (SYK) to $315 from $402 and keeps a Hold rating on the shares.
Stryker price target lowered to $418 from $454 at Needham
Needham lowered the firm’s price target on Stryker (SYK) to $418 from $454 and keeps a Buy rating on the shares after its Q1 earnings miss. Organic sales growth slowed…
Stryker price target lowered to $400 from $435 at Canaccord
Canaccord lowered the firm’s price target on Stryker (SYK) to $400 from $435 and keeps a Buy rating on the shares. The firm said they delivered a mixed quarter, with…
Stryker misses quarterly estimates on muted demand for medical devices
U.S. medical device maker Stryker on Thursday maintained its full-year profit outlook but missed Wall Street estimates for first-quarter profit and revenue, weighed down by softer demand for implants...
Stryker First-Quarter Sales, Profit Rise as it Dealt with Cyberattack
The medical-device company posted a profit of $745 million, up from $654 million in the same quarter a year ago.
Stryker Earnings Call Transcript: Q1 2026
Q1 2026 results were disrupted by a cyber incident, impacting sales and margins, but strong demand and operational recovery support reaffirmed full-year guidance for 8%-9.5% organic sales growth and $14.90-$15.10 adjusted EPS. M&A activity and new product launches are expected to drive growth.
Stryker Earnings release: Q1 2026
Stryker released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Stryker Quarterly report: Q1 2026
Stryker has published its Q1 2026 quarterly earnings report on April 30, 2026.